Organon & Co. (OGN) – What Are Investment Firms Saying About This Stock?

Organon & Co. (NYSE:OGN) has earned an average rating of “Reduce” from the seven brokerages that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating and five have issued a hold rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $11.40.

Separately, Weiss Ratings upgraded Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th.

Organon & Co. Stock Down 0.1%

OGN opened at $13.74 on Tuesday. The company has a fifty day moving average of $13.73 and a two-hundred day moving average of $12.87. The stock has a market capitalization of $3.61 billion, a price-to-earnings ratio of 17.85, a PEG ratio of 1.27 and a beta of 1.55. Organon & Co. has a fifty-two week low of $5.69 and a fifty-two week high of $13.83. The company has a debt-to-equity ratio of 8.43, a quick ratio of 1.44 and a current ratio of 1.95.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 10th. Investors of record on Friday, August 14th were issued a $0.02 dividend. The ex-dividend date of this dividend was Friday, August 14th. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. Organon & Co.’s dividend payout ratio is presently 10.39%.

Hedge Funds Weigh In On Organon & Co.

Hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System grew its position in shares of Organon & Co. by 34.8% in the first quarter. California State Teachers Retirement System now owns 327,075 shares of the company’s stock valued at $1,959,000 after purchasing an additional 84,497 shares during the period. WINTON GROUP Ltd purchased a new stake in shares of Organon & Co. during the second quarter worth about $6,904,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Organon & Co. during the 2nd quarter worth about $770,000. Orographic Financial Advisors LLC acquired a new position in shares of Organon & Co. during the 1st quarter worth about $1,522,000. Finally, Sei Investments Co. raised its position in shares of Organon & Co. by 82.0% during the 1st quarter. Sei Investments Co. now owns 190,057 shares of the company’s stock worth $1,139,000 after purchasing an additional 85,657 shares during the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a global health care company focused on improving the health and quality of life of women throughout their lives. The company develops, manufactures and commercializes prescription medicines and other health care products, with operations serving patients and health care providers in markets around the world.

Organon’s women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as medicines and technologies related to fertility, pregnancy and other reproductive health needs.